Pharma8k's (Page 8)

Onconetix (ONCO) Subsidiary Amends Labcorp Agreement for Proclarix PRIME Study, Adds $300,000 Milestone

10 Dec 2025 SEC Filing 8-K Partnerships $ONCO

Onconetix (ONCO) Subsidiary Amends Labcorp Agreement for Proclarix PRIME Study, Adds $300,000 Milestone

Onconetix (ONCO) subsidiary Proteomedix AG amended its license agreement with Labcorp to include the PRIME Study for Proclarix, with milestone payments up to $300,000.

Factual headline with ticker: Oncotelic Therapeutics (OTLC) Completes $275,000 Private Placement Offering

10 Dec 2025 SEC Filing 8-K Financing $OTLC

Factual headline with ticker: Oncotelic Therapeutics (OTLC) Completes $275,000 Private Placement Offering

Oncotelic Therapeutics (OTLC) completed a $275,000 private placement offering of 11 units to accredited investors on December 4, 2025.

Hyperion DeFi (HYPD) Faces Delisting and Bankruptcy Risks in SEC Filing

10 Dec 2025 SEC Filing 8-K $HYPD

Hyperion DeFi (HYPD) Faces Delisting and Bankruptcy Risks in SEC Filing

Hyperion DeFi (HYPD) disclosed delisting and bankruptcy risks in an 8-K filing on December 10, 2025, citing HYPE token treasury instability.

Apimeds Pharmaceuticals US (APUS) Announces Merger and $120.9M Financing in SEC Filing

10 Dec 2025 SEC Filing 8-K $APUS

Apimeds Pharmaceuticals US (APUS) Announces Merger and $120.9M Financing in SEC Filing

Apimeds Pharmaceuticals US (APUS) filed an 8-K disclosing a merger agreement and a $120.9 million securities purchase amendment.

RenovoRx, Inc. (RNXT) Files Form 4 with SEC on December 8, 2025

08 Dec 2025 SEC Filing 4 Insider Trading $RNXT

RenovoRx, Inc. (RNXT) Files Form 4 with SEC on December 8, 2025

RenovoRx, Inc. (RNXT) submitted a Form 4 filing to the SEC on December 8, 2025.